Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Peringkat dalam Saham #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicelโ€”a specialized cell therapyโ€”has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Harga Saham
$0.0327
Terakhir disinkronkan: 2025-06-17
Kapitalisasi Pasar
$4.34M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
IL
Perdagangan Gamida Cell Ltd. (GMDA)

Kategori

Rasio P/B untuk Gamida Cell Ltd. (GMDA)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Gamida Cell Ltd., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Gamida Cell Ltd. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE